Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning

Toxicology and Applied Pharmacology

Volumn 243, Issue 3, 2010, Pages 300-314

  Auerbach, Scott S ^a   Shah, Ruchir R ^b   Mav, Deepak ^b   Smith, Cynthia S ^a   Walker, Nigel J ^a   Vallant, Molly K ^a   Boorman, Gary A ^a   Irwin, Richard D ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b GENERAL DYNAMICS   (United States)

Author keywords

Alkenylbenzene; Cancer; Liver; Prediction; Rat; Toxicogenomics

Indexed keywords

1 AMINO 2,4 DIBROMOANTHRAQUINONE; AFLATOXIN B1; ALANINE AMINOTRANSFERASE; ASCORBIC ACID; DIMETHYLNITROSAMINE; ESTRAGOLE; FLAVORING AGENT; FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; METHYLEUGENOL; PARACETAMOL; PROTEIN ADAM8; PROTEIN MYBL2; PROTEIN WWOX; SAFROLE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ACCURACY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CLASSIFICATION; CLINICAL CHEMISTRY; CONTROLLED STUDY; EXPOSURE; GENE EXPRESSION; HEMATOLOGY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER HISTOLOGY; MALE; MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; RAT; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

ANIMALS; ARTIFICIAL INTELLIGENCE; BENZENE DERIVATIVES; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; CARCINOGENS; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVORING AGENTS; FOOD ADDITIVES; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; LIVER; LIVER NEOPLASMS; MALE; MUTAGENICITY TESTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; RNA; TOXICOGENETICS;

RATTUS;

EID: 77049090813     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.11.021     Document Type: Article

References (77)

1. Allen D.G., Pearse G., Haseman J.K., and Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 32 (2004) 393-401
2. Ben-Zur T., Feige E., Motro B., and Wides R. The mammalian Odz gene family: homologs of a Drosophila pair-rule gene with expression implying distinct yet overlapping developmental roles. Dev. Biol. 217 (2000) 107-120
3. Benigni, R., Netzeva, T.I., Benfenati, E., Bossa, C., Franke, R., Helma, C., Hulzebos, E., Marchant, C., Richard, A., Woo, Y.T., and Yang, C. (2007). The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens.
4. Benigni R., and Zito R. The second National Toxicology Program comparative exercise on the prediction of rodent carcinogenicity: definitive results. Mutat. Res. 566 (2004) 49-63
5. Bristol D. NTP. Toxicity Report 82 (2009)
6. Bucher J.R., and Portier C. Human carcinogenic risk evaluation, Part V: the National Toxicology Program vision for assessing the human carcinogenic hazard of chemicals. Toxicol. Sci. 82 (2004) 363-366
7. Chedotal A., Kerjan G., and Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ. 12 (2005) 1044-1056
8. Chhabra R.S., Huff J.E., Schwetz B.S., and Selkirk J. An overview of prechronic and chronic toxicity/carcinogenicity experimental study designs and criteria used by the National Toxicology Program. Environ. Health Perspect. 86 (1990) 313-321
9. Cohen S.M. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 80 (2004) 225-229
10. Eastin W.C., Mennear J.H., Tennant R.W., Stoll R.E., Branstetter D.G., Bucher J.R., McCullough B., Binder R.L., Spalding J.W., and Mahler J.F. Tg.AC genetically altered mouse: assay working group overview of available data. Toxicol. Pathol. 29 Suppl (2001) 60-80
11. Elcombe C.R., Odum J., Foster J.R., Stone S., Hasmall S., Soames A.R., Kimber I., and Ashby J. Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Environ. Health Perspect. 110 (2002) 363-375
12. Ellinger-Ziegelbauer H., Gmuender H., Bandenburg A., and Ahr H.J. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637 (2008) 23-39
13. Fielden M.R., Brennan R., and Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99 (2007) 90-100
14. Garman K.S., Nevins J.R., and Potti A. Genomic strategies for personalized cancer therapy. Hum. Mol. Genet. 16 Spec No. 2 (2007) R226-R232
15. Gold L.S., Manley N.B., Slone T.H., Rohrbach L., and Garfinkel G.B. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol. Sci. 85 (2005) 747-808
16. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., and Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
17. Guyon I., Weston J., Barnhill S., and Vapnik V. Gene selection for cancer classification using support vector machines. Mach. Learn. 46 (2002) 389-422
18. Hagan E.C., Jenner P.M., Jones W.I., Fitzhugh O.G., Long E.L., Brouwer J.G., and Webb W.K. Toxic properties of compounds related to safrole. Toxicol. Appl. Pharmacol. 7 (1965) 18-24
19. Huff, J. (1998). Carcinogenesis results in animals predict cancer risks to humans. In Maxcy-Rosenau-Last public health & preventive medicine (R.B. Wallace, Ed.), pp. 543-550, 567-569. Appleton & Lange, Stamford, Conn.
20. IARC. Some naturally occurring compounds. In: IARC (Ed). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (1976), IARC Scientific Publishing, Lyon 51-72
21. IARC. Some N-Nitroso compounds. In: IARC (Ed). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (1978), IARC Scientific Publishing, Lyon 125-176
22. Iida M., Anna C.H., Holliday W.M., Collins J.B., Cunningham M.L., Sills R.C., and Devereux T.R. Unique patterns of gene expression changes in liver after treatment of mice for 2 weeks with different known carcinogens and non-carcinogens. Carcinogenesis 26 (2005) 689-699
23. Iliopoulos D., Guler G., Han S.Y., Druck T., Ottey M., McCorkell K.A., and Huebner K. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 232 (2006) 27-36
24. Isfort R.J., Kerckaert G.A., and LeBoeuf R.A. Comparison of the standard and reduced pH Syrian hamster embryo (SHE) cell in vitro transformation assays in predicting the carcinogenic potential of chemicals. Mutat. Res. 356 (1996) 11-63
25. Ito N., Tamano S., and Shirai T. A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci. 94 (2003) 3-8
26. Jacobs A. Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing?. Toxicol. Sci. 88 (2005) 18-23
27. Judson R., Richard A., Dix D.J., Houck K., Martin M., Kavlock R., Dellarco V., Henry T., Holderman T., Sayre P., Tan S., Carpenter T., and Smith E. The toxicity data landscape for environmental chemicals. Environ. Health Perspect. 117 (2009) 685-695
28. Kerckaert G.A., Brauninger R., LeBoeuf R.A., and Isfort R.J. Use of the Syrian hamster embryo cell transformation assay for carcinogenicity prediction of chemicals currently being tested by the National Toxicology Program in rodent bioassays. Environ. Health Perspect. 104 Suppl 5 (1996) 1075-1084
29. Kramer J.A., Curtiss S.W., Kolaja K.L., Alden C.L., Blomme E.A., Curtiss W.C., Davila J.C., Jackson C.J., and Bunch R.T. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 17 (2004) 463-470
30. Lambert, I.B., Singer, T.M., Boucher, S.E., and Douglas, G.R. (2005). Detailed review of transgenic rodent mutation assays.
31. Long E.L., Nelson A.A., Fitzhugh O.G., and Hansen W.H. Liver tumors produced in rats by feeding safrole. Arch. Pathol. 75 (1963) 595-604
32. McAvoy S., Zhu Y., Perez D.S., James C.D., and Smith D.I. Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. Genes Chromosomes Cancer 47 (2008) 165-174
33. Mercier I., Vuolo M., Madan R., Xue X., Levalley A.J., Ashton A.W., Jasmin J.F., Czaja M.T., Lin E.Y., Armstrong R.C., Pollard J.W., and Kitsis R.N. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ. 12 (2005) 682-686
34. Miller E.C., Swanson A.B., Phillips D.H., Fletcher T.L., Liem A., and Miller J.A. Structure-Activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 43 (1983) 1124-1134
35. Mochizuki S., and Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 98 (2007) 621-628
36. Muir D.C., and Howard P.H. Are there other persistent organic pollutants? A challenge for environmental chemists. Environ. Sci. Technol. 40 (2006) 7157-7166
37. Nakayama K., Kawano Y., Kawakami Y., Moriwaki N., Sekijima M., Otsuka M., Yakabe Y., Miyaura H., Saito K., Sumida K., and Shirai T. Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study. Toxicol. Appl. Pharmacol. 217 (2006) 299-307
38. Nie A.Y., McMillian M., Parker J.B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., and Lord P.G. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45 (2006) 914-933
39. Noble W.S. What is a support vector machine?. Nat. Biotechnol. 24 (2006) 1565-1567
40. NTP. Carcinogenesis studies of eugenol (CAS No. 97-53-0) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 223 (1983) 1-159
41. NTP. NTP carcinogenesis bioassay of l-ascorbic acid (vitamin C) (CAS No. 50-81-7) in F344/N rats and B6C3F1 mice (feed study). Natl. Toxicol. Program Tech. Rep. Ser. 247 (1983) 1-172
42. NTP. NTP toxicology and carcinogenesis studies of acetaminophen (CAS No. 103-90-2) in F344 rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 394 (1993) 1-274
43. NTP. NTP toxicology and carcinogenesis studies of 1-amino-2,4-dibromoanthraquinone (CAS No. 81-49-2) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 383 (1996) 1-370
44. NTP. NTP toxicology and carcinogenesis studies of methyleugenol (CAS NO. 93-15-2) in F344/N rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 491 (2000) 1-412
45. NTP (2008). TR-551-NTP technical report on the toxicology and carcinogenesis studies of isoeugenol.
46. Parry E.M., Parry J.M., Corso C., Doherty A., Haddad F., Hermine T.F., Johnson G., Kayani M., Quick E., Warr T., and Williamson J. Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis 17 (2002) 509-521
47. Pirooznia M., Yang J.Y., Yang M.Q., and Deng Y. A comparative study of different machine learning methods on microarray gene expression data. BMC Genomics 9 Suppl. 1 (2008) S13
48. Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., and Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res. 50 (1990) 7415-7421
49. Randerath K., Haglund R.E., Phillips D.H., and Reddy M.V. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis 5 (1984) 1613-1622
50. REACH (2008). ECHA-list of pre-registered substances.
51. Ressom H.W., Varghese R.S., Zhang Z., Xuan J., and Clarke R. Classification algorithms for phenotype prediction in genomics and proteomics. Front. Biosci. 13 (2008) 691-708
52. Rozman K.K. The role of time in toxicology or Haber's c × t product. Toxicology 149 (2000) 35-42
53. Saeys Y., Inza I., and Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 23 (2007) 2507-2517
54. Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur. J. Cancer 41 (2005) 2479-2484
55. Sasaki Y.F., Sekihashi K., Izumiyama F., Nishidate E., Saga A., Ishida K., and Tsuda S. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and U.S. NTP Carcinogenicity Database. Crit. Rev. Toxicol. 30 (2000) 629-799
56. Schwettmann L., Wehmeier M., Jokovic D., Aleksandrova K., Brand K., Manns M.P., Lichtinghagen R., and Bahr M.J. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J. Hepatol. 49 (2008) 243-250
57. Sekine S., Lan B.Y., Bedolli M., Feng S., and Hebrok M. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology (Baltimore, Md 43 (2006) 817-825
58. Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 33 (1977) 386-389
59. Statnikov A., Li C., and Aliferis C.F. Effects of environment, genetics and data analysis pitfalls in an esophageal cancer genome-wide association study. PLoS ONE 2 (2007) e958
60. Statnikov A., Wang L., and Aliferis C.F. A comprehensive comparison of random forests and support vector machines for microarray-based cancer classification. BMC Bioinformatics 9 (2008) 319
61. Storer R.D., French J.E., Haseman J., Hajian G., LeGrand E.K., Long G.G., Mixson L.A., Ochoa R., Sagartz J.E., and Soper K.A. P53+/- hemizygous knockout mouse: overview of available data. Toxicol. Pathol. 29 Suppl (2001) 30-50
62. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15545-15550
63. Takigawa Y., and Brown A.M. Wnt signaling in liver cancer. Curr. Drug Target 9 (2008) 1013-1024
64. Tennant R.W., Margolin B.H., Shelby M.D., Zeiger E., Haseman J.K., Spalding J., Caspary W., Resnick M., Stasiewicz S., Anderson B., et al. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236 (1987) 933-941
65. Thavathiru E., Ludes-Meyers J.H., MacLeod M.C., and Aldaz C.M. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol. Carcinog. 44 (2005) 174-182
66. Thomas R.S., Pluta L., Yang L., and Halsey T.A. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 97 (2007) 55-64
67. Truhaut R., Le Bourhis B., Attia M., Glomot R., Newman J., and Caldwell J. Chronic toxicity/carcinogenicity study of trans-anethole in rats. Food Chem. Toxicol. 27 (1989) 11-20
68. Uehara T., Hirode M., Ono A., Kiyosawa N., Omura K., Shimizu T., Mizukawa Y., Miyagishima T., Nagao T., and Urushidani T. A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. Toxicology 250 1 (2008) 15-26
69. USEPA (2004). What is the TSCA chemical substance inventory?
70. Usui T., Mutai M., Hisada S., Takoaka M., Soper K.A., McCullough B., and Alden C. CB6F1-rasH2 mouse: overview of available data. Toxicol. Pathol. 29 Suppl (2001) 90-108
71. Van den Berg M., Birnbaum L., Bosveld A.T., Brunstrom B., Cook P., Feeley M., Giesy J.P., Hanberg A., Hasegawa R., Kennedy S.W., Kubiak T., Larsen J.C., van Leeuwen F.X., Liem A.K., Nolt C., Peterson R.E., Poellinger L., Safe S., Schrenk D., Tillitt D., Tysklind M., Younes M., Waern F., and Zacharewski T. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106 (1998) 775-792
72. van Kreijl C.F., McAnulty P.A., Beems R.B., Vynckier A., van Steeg H., Fransson-Steen R., Alden C.L., Forster R., van der Laan J.W., and Vandenberghe J. Xpa and Xpa/p53+/- knockout mice: overview of available data. Toxicol. Pathol. 29 Suppl (2001) 117-127
73. Weiske J., Albring K.F., and Huber O. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20344-20349
74. Whitfield M.L., George L.K., Grant G.D., and Perou C.M. Common markers of proliferation. Nat. Rev. Cancer 6 (2006) 99-106
75. Wiseman R.W., Miller E.C., Miller J.A., and Liem A. Structure-Activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J x C3H/HeJ F1 mice. Cancer Res. 47 (1987) 2275-2283
76. Wogan G.N., and Newberne P.M. Dose-response of aflatoxin B1 carcinogenesis in the rat. Cancer Res. 27 (1967) 2370-2376
77. Yang J., and Zhang W. WWOX tumor suppressor gene. Histol. Histopathol. 23 (2008) 877-882